Dr. Rahul Aggarwal, MD
Claim this profileUniversity of California, San Francisco
Expert in Prostate Cancer
Studies Cancer
24 reported clinical trials
36 drugs studied
About Rahul Aggarwal, MD
Education:
- Obtained MD from Northwestern University The Feinberg School of Medicine, Class of 2006.
Experience:
- Completed Residency in Internal Medicine at the University of California, San Francisco (UCSF), 2006-2009.
- Undertook Fellowship in Hematology and Medical Oncology at UCSF, 2010-2013.
- Co-Leader of the GU Medical Oncology program and Medical Oncologist within the Division of Hematology/Oncology at UCSF Health.
- Specializes in genitourinary cancers, with a focus on novel therapies and imaging for advanced solid tumor malignancies.
Area of expertise
1Prostate Cancer
Global LeaderStage IV
Stage III
RB1 positive
2Cancer
Stage IV
Stage III
EphA5 positive
Affiliated Hospitals
Clinical Trials Rahul Aggarwal, MD is currently running
TAB004 + Toripalimab
for Solid Cancers
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab.
Recruiting1 award Phase 110 criteria
ZEN-3694 + Enzalutamide + Pembrolizumab
for Prostate Cancer
This phase II trial investigates how well ZEN-3694, enzalutamide, and pembrolizumab work in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). ZEN-3694 blocks the expression of the MYC gene to prevent cellular growth in certain types of tumors, including castrate resistant prostate cancer. Enzalutamide has been shown to block testosterone from reaching prostate cancer cells by binding to a receptor on prostate cancer cells, called androgen receptors. This works similar to a lock and key. When enzalutamide (key) inserts into the androgen receptor (lock) testosterone cannot attach to the androgen receptor, which slows the growth of tumor cells and may cause them to shrink. Pembrolizumab is a monoclonal antibody (proteins that can protect the body from foreign organisms, such as bacteria and viruses) designed to block a specific control switch which may be activated by tumor cells to overcome the body's natural immune system defenses. It also enhances the activity of the body's immune cells against tumor cells. The purpose of this study is to find out the effects ZEN-3694, enzalutamide, and pembrolizumab on patients with metastatic castration-resistant prostate cancer who have previously experienced disease progression.
Recruiting1 award Phase 219 criteria
More about Rahul Aggarwal, MD
Clinical Trial Related4 years of experience running clinical trials · Led 24 trials as a Principal Investigator · 13 Active Clinical TrialsTreatments Rahul Aggarwal, MD has experience with
- Pembrolizumab
- Enzalutamide
- Apalutamide
- FOR46
- Gallium-68 Citrate PET
- Pyruvate (13C)
Breakdown of trials Rahul Aggarwal, MD has run
Prostate Cancer
Cancer
Solid Tumors
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rahul Aggarwal, MD specialize in?
Rahul Aggarwal, MD focuses on Prostate Cancer and Cancer. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are Stage III.
Is Rahul Aggarwal, MD currently recruiting for clinical trials?
Yes, Rahul Aggarwal, MD is currently recruiting for 13 clinical trials in San Francisco California. If you're interested in participating, you should apply.
Are there any treatments that Rahul Aggarwal, MD has studied deeply?
Yes, Rahul Aggarwal, MD has studied treatments such as Pembrolizumab, Enzalutamide, Apalutamide.
What is the best way to schedule an appointment with Rahul Aggarwal, MD?
Apply for one of the trials that Rahul Aggarwal, MD is conducting.
What is the office address of Rahul Aggarwal, MD?
The office of Rahul Aggarwal, MD is located at: University of California, San Francisco, San Francisco, California 94143 United States. This is the address for their practice at the University of California, San Francisco.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.